Parker Institute For Cancer Immunotherapy
Karen Knudsen, MBA, PhD, named CEO of Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy has named Karen E. Knudsen, MBA, PhD, as its new CEO, according to a press release.
Crystal L. Mackall, MD, to receive award for cancer gene and cell therapy research
Crystal L. Mackall, MD, will receive this year’s Edward Netter Leadership Award from Alliance for Cancer Gene Therapy.
Parker Institute adds Dana-Farber, Gladstone Institutes to cancer research collaboration
Parker Institute for Cancer Immunotherapy added Dana-Farber Cancer Institute and Gladstone Institutes to its immuno-oncology research partnership network.
Immunotherapy combo fails to extend disease-free survival in high-risk kidney cancer
The combination of nivolumab and ipilimumab after nephrectomy failed to extend DFS among patients with localized renal cell carcinoma at high risk for relapse, results of the phase 3 CheckMate 914 trial showed.
Parker Institute for Cancer Immunotherapy awards $4.5 million to early career researchers
Project aims to improve cancer cell therapies through gene expression profiling
Tumor gene expression profiles have become standard practice to help guide treatment of several cancer types.
CAR-T with synthetic binder shows ‘very promising’ results in advanced multiple myeloma
A novel chimeric antigen receptor T-cell therapy induced responses in the first 12 evaluable patients with relapsed or refractory multiple myeloma treated in a phase 1 dose-escalation trial.
Gene-edited T-cell therapy shows ‘promising efficacy’ for rare sarcomas
Nearly 40% of patients with advanced or metastatic synovial sarcoma or myxoid/round cell liposarcoma responded to therapy with afamitresgene autoleucel, according to results of a phase 2 study.
Tumor-infiltrating lymphocytes show ‘provocative’ response rates in advanced melanoma
More than half of patients with heavily pretreated melanoma responded to therapy with unselected tumor-infiltrating lymphocytes, according to results of a retrospective study.
Product composition, immune biomarkers linked to CAR-T efficacy
Product attributes appeared associated with more potent and durable responses to axicabtagene ciloleucel among patients with follicular lymphoma, according to an analysis of the ZUMA-5 trial.